SCHEMBL2961579

SCHEMBL2961579

CCc1cc2c(C(=O)CC(=O)OC)cccn2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.36
TP53 P04637 2/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
KDM4E B2RXH2 3/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
NPC1 O15118 2/20 0.32
MAPT P10636 2/20 0.32
NAMPT P43490 1/20 0.32
RAB9A P51151 1/20 0.32
KLF5 Q13887 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MIF P14174 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963896 0.85 HSP90AB1 (0.35) PDE4BTP53SMN1; SMN2KMT2AMEN1
SCHEMBL3222485 0.81 DHODH (0.40) TDP1KDM4EALDH1A1HSD17B10EGFR
SCHEMBL2961374 0.81 KMT2A (0.38) POLBSMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL13266060 0.81 PARP1 (0.33) PDE4BTP53SMN1; SMN2KMT2AMEN1
SCHEMBL2965155 0.79 PDE4B (0.35) PDE4BTP53POLBTDP1SMN1; SMN2
SCHEMBL2962453 0.76 SPR (0.34) PDE4BKDM4EMAPTALDH1A1LMNA
SCHEMBL2956927 0.76 PDE4B (0.61) PDE4B
SCHEMBL2963981 0.75 KDM4E (0.36) TP53POLBKDM4EKMT2AMEN1
SCHEMBL13266037 0.73 MIF (0.35) PDE4BKMT2AMEN1NPSR1ALDH1A1
SCHEMBL2967764 0.72 MIF (0.35) PDE4BTP53KMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763617-B2 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-7763617-B2 Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-07-27 US disclosed
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207902-A1 Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient PDE5A, PDE3A, PDE3B PDE4B 7/4885TP53 4813/4885POLB 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.